Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare neurological disorder, which is characterized by progressive weakness and impaired sensory function in the legs and arms mainly caused by damage to the myelin sheath of the peripheral nerves.
&nbsp;
CIDP symptoms include tingling or numbness (beginning in the toes and fingers), weakness of the arms and legs, loss of deep tendon reflexes (areflexia), fatigue, and abnormal sensations.
&nbsp;
CIDP can be categorized into Typical CIDP and Atypical CIDP. Typical CIDP is the presence of both proximal and distal muscle weakness. Atypical CIDP includes the Multifocal acquired demyelinating sensory and motor neuropathy, Distal acquired demyelinating symmetric neuropathy, Focal CIDP, Pure motor CIDP, Pure sensory CIDP.&nbsp;
&nbsp;
Chronic Inflammatory Demyelinating Polyneuropathy Epidemiological Segmentation&nbsp;
The Epidemiological Segmentation of Chronic Inflammatory Demyelinating Polyneuropathy in 7MM from 2017 to 2030 is segmented as:-&nbsp;
<ul>
<li>Total Prevalent Pool of Chronic Inflammatory Demyelinating Polyneuropathy</li>
<li>Gender-specific Prevalent Pool of Chronic Inflammatory Demyelinating Polyneuropathy</li>
<li>Age-specific Prevalent Pool of Chronic Inflammatory Demyelinating Polyneuropathy</li>
<li>Clinical subtype based Diagnosed Prevalent Pool of Chronic Inflammatory Demyelinating Polyneuropathy&nbsp;</li>
</ul>
&nbsp;
Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology&nbsp;
<ul>
<li>The total prevalent population of Chronic Inflammatory Demyelinating Polyneuropathy in 7MM in 2017 was observed to be 44,700&nbsp;</li>
<li>The Prevalent cases of CIDP in the US in 2017 was 28,968&nbsp;</li>
</ul>
&nbsp;
<a style="color: #0066cc; background-color: transparent;" href="https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market" target="_blank" rel="noopener noreferrer">Chronic Inflammatory Demyelinating Polyneuropathy Market</a>
Market Size of Chronic Inflammatory Demyelinating Polyneuropathy in the 7MM in 2017 was 968 Million&nbsp;&nbsp;
&nbsp;
Chronic Inflammatory Demyelinating Polyneuropathy Market Drivers
<ul>
<li>Rising Prevalence and Awareness</li>
<li>Advanced Technologies</li>
<li>Increasing R&amp;D Activities</li>
</ul>
&nbsp;
Chronic Inflammatory Demyelinating Polyneuropathy Market Barriers
<ul>
<li>Lack of awareness</li>
<li>Drug Pricing</li>
</ul>
&nbsp;
Chronic Inflammatory Demyelinating Polyneuropathy Emerging Drugs
The emerging drugs of the Chronic Inflammatory Demyelinating Polyneuropathy market are&nbsp;
<ul>
<li>GGS-CIDP</li>
<li>Newgam&nbsp;</li>
<li>HyQvia</li>
<li>I10E</li>
<li>MD-1003</li>
<li>M254</li>
</ul>
And many others.&nbsp;&nbsp;
&nbsp;
Chronic Inflammatory Demyelinating Polyneuropathy Key Players
The key players in the Chronic Inflammatory Demyelinating Polyneuropathy market are
<ul>
<li>Teijin Pharma</li>
<li>OctaPharma</li>
<li>Shire/ Takeda</li>
<li>LFB</li>
<li>MedDay Pharmaceuticals</li>
<li>Momenta Pharmaceuticals</li>
</ul>
And many others.&nbsp;

Chronic Inflammatory Demyelinating Polyneuropathy Market

Chronic Inflammatory Demyelinating Polyneuropathy Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.